Share Prices & Company Research

Stockbroking

GlaxoSmithKline

Current Price 1821.75p Bid 1822.00p Ask 1823.00p Change 0.44%
Last Updated: 14/12/2025 13:47. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

Financial Highlights Year Ended 31/12/2024

Revenue
£31,376.00m
Operating Profit/Loss
£4,021.00m
Dividend yield (%)
4.50
Total dividend for year
n/ap
Dividend cover
2.61
P/E Ratio
8.40
More Financials

Key Personnel

Ms Emma Walmsley
Chief Executive Officer
Ms Julie Brown
Chief Finance Officer
Mr Hal Barron
Chief Scientific Officer
Mr Elizabeth (Liz) McKee Anderson
Independent Non-Executive Director
Mr Harry (Hal) C. Dietz
Independent Non-Executive Director
Mr Vishal Sikka
Independent Non-Executive Director
Mr Jonathan Symonds
Non-Executive Chairman
Dr Anne Beal
Non-Executive Director
Dr Gavin Screaton
Non-Executive Director
Dr Jeannie Lee
Non-Executive Director
Mr Charles Bancroft
Non-Executive Director
Mr Wendy Becker
Non-Executive Director

Stock Details

EPIC
GSKL
ISIN
GB0009252882
Shares in Issue
4,870.09m
Market cap
£88,720.87m

Analyst Views (4)

Strong Buy
 
0%
Buy
 
50.00%
Hold
 
25.00%
Sell
 
25.00%
Strong Sell
 
0%
This information is provided by Web Financial Group (UK) Limited. It is subject to change without notice and doesn't reflect the views held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
1,821.75p
Bid Price
1,822.00p
Ask Price
1,823.00p
Volume
979,196
Change Today
8.00p
% Change Today
0.44%
Open
1,817.00p
Previous Close
1,821.75p
Intraday High
1,837.00p
Intraday Low
1,815.50p
52 Week High
1,837.00p
52 Week Low
1,262.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

More Charts

News

GSK gets preliminary nod for two respiratory drugs in Europe 12/12/2025 13:57:55 GSK's Arexy receives EU green light 12/12/2025 07:20:13 GSK's lung cancer drug granted orphan status by FDA 10/12/2025 07:18:30 Berenberg raises target price on GSK 25/11/2025 09:22:52 GSK files suit against AnaptysBio over licensing rights 21/11/2025 07:02:35 GSK posts better-than-expected Q3, upgrades guidance 29/10/2025 07:20:17 GSK lung cancer treatment gets EU orphan drug status 28/10/2025 07:14:21 GSK shares lift on prostate cancer deal 27/10/2025 09:33:40 GSK's Blenrep receives US FDA approval 24/10/2025 07:03:18 GSK advances low-carbon inhaler, halts latozinemab study after mixed data 22/10/2025 08:12:15 GSK reports positive trial data for oral cUTI treatment, secures EU backing for simplified shingles vaccine 21/10/2025 07:13:21 GSK shingles vaccine approved for expanded use in China 14/10/2025 07:07:42 Emma Walmsley to step down as chief executive of GSK 29/09/2025 07:01:27 GSK plans $30bn US investment as pharma faces tariff threat 17/09/2025 07:03:41 GSK gepotidacin edges closer to landmark approval for gonorrhoea 11/08/2025 07:15:28 GSK and CureVac secure $740m payout in mRNA patent settlement 08/08/2025 07:36:37 GSK Q2 revenues grow, reiterates FY guidance 30/07/2025 07:36:21 GSK and Hengrui unveil development deal worth up to $12bn 28/07/2025 07:17:10 FDA votes against overall benefit/risk profile of GSK's multiple myeloma candidate at proposed dosage 18/07/2025 07:42:58 US FDA approves new format of GSK's Shingrix 17/07/2025 09:21:11 US FDA to review GSK bid to extend use of respiratory virus drug 14/07/2025 07:03:37 EMA accepts marketing authorisation application for GSK's linerixibat 23/06/2025 11:07:56 GSK hoping to expand Arexvy usage in Japan 20/06/2025 07:19:43 GSK's RSV vaccine accepted for regulatory review by EMA 13/06/2025 07:01:26 Berenberg downgrades GSK to 'hold' ahead of product rollouts 03/06/2025 10:18:12

Income Statement

Year End Date
31 Dec 2024
31 Dec 2023
 
£ (M)
£ (M)
Continuing Operations
Revenue
31,376.00
30,328.00
Operating Profit/Loss
4,021.00
6,745.00
Net Interest
-547.00
-677.00
Pre-Tax Profit
3,477.00
6,064.00
Profit After Tax from continuing operations
2,951.00
5,308.00
Discontinued Operations
Profit After Tax
n/a
n/a
Profit/Loss for the Year
2,951.00
5,308.00
Attributable to:
Equity Holders of Parent Company
2,575.00
4,928.00
Minority Interests
376.00
380.00
Total Dividend Paid
n/ap
n/ap
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2024
31 Dec 2023
Basic
63.20p
121.60p
Diluted
62.20p
119.90p
Adjusted
159.30p
155.10p
Dividend per Share
n/ap
n/ap

Assets

Year End Date
31 Dec 2024
31 Dec 2023
 
£ (M)
£ (M)
Non-Current Assets
Property, Plant & Equipment
10,073.00
9,957.00
Intangible Assets
22,497.00
21,579.00
Investment Properties
n/a
n/a
Investments
1,196.00
1,192.00
Other Financial Assets
1.00
n/a
Other Non-Current Assets
8,699.00
7,633.00
Current Assets
Inventories
5,669.00
5,498.00
Trade & Other Receivables
6,836.00
7,385.00
Cash at Bank & In Hand
3,870.00
2,936.00
Current Asset Investments
n/a
n/a
Other Current Assets
619.00
2,749.00
Other Assets
3.00
76.00
Total Assets
59,463.00
59,005.00

Liabilities

Year End Date
31 Dec 2024
31 Dec 2023
 
£ (M)
£ (M)
Current Liabilities
Borrowings
2,349.00
2,813.00
Other Current Liabilities
19,348.00
18,255.00
Total Current Liabilities
21,697.00
21,068.00
Non-Current Liabilities
Borrowings
14,637.00
15,205.00
Provisions
971.00
806.00
Other Non-Current Liabilities
9,072.00
9,131.00
Total Non-Current Liabilities
24,680.00
25,142.00
Other Liabilities
n/a
n/a
Total Liabilities
46,377.00
46,210.00

Net Assets

Year End Date
31 Dec 2024
31 Dec 2023
 
£ (M)
£ (M)
Net Assets
13,086.00
12,795.00

Capital & Reserves

Year End Date
31 Dec 2024
31 Dec 2023
 
£ (M)
£ (M)
Share Capital
1,348.00
1,348.00
Share Premium Account
3,473.00
3,451.00
Other Reserves
1,054.00
1,309.00
Retained Earnings
7,796.00
7,239.00
Shareholders Funds
13,671.00
13,347.00
Minority Interests/Other Equity
-585.00
-552.00
Total Equity
13,086.00
12,795.00

Dividend History

Type
Ex-Dividend Date
Payment Date
Payment
Q3
13 Nov 2025
08 Jan 2026
16.00p
Q2
14 Aug 2025
09 Oct 2025
16.00p
Q1
16 May 2025
10 Jul 2025
16.00p
Q1
15 May 2025
10 Jul 2025
16.00p
Q4
21 Feb 2025
10 Apr 2025
16.00p
Q4
20 Feb 2025
10 Apr 2025
16.00p
Q3
15 Nov 2024
09 Jan 2025
15.00p
Q3
14 Nov 2024
09 Jan 2025
15.00p
Q2
15 Aug 2024
10 Oct 2024
15.00p
Q1
16 May 2024
11 Jul 2024
15.00p
Q4
22 Feb 2024
11 Apr 2024
16.00p
Q3
16 Nov 2023
11 Jan 2024
14.00p
Q2
17 Aug 2023
12 Oct 2023
14.00p
Q1
18 May 2023
13 Jul 2023
14.00p
Q4
23 Feb 2023
13 Apr 2023
13.75p
Q3
17 Nov 2022
12 Jan 2023
13.75p
Q2
18 Aug 2022
06 Oct 2022
16.25p
Q1
19 May 2022
01 Jul 2022
14.00p
Q4
24 Feb 2022
07 Apr 2022
23.00p
Q3
18 Nov 2021
13 Jan 2022
19.00p
Q2
19 Aug 2021
07 Oct 2021
19.00p
Q1
20 May 2021
08 Jul 2021
19.00p
Q4
18 Feb 2021
08 Apr 2021
23.00p
Q3
12 Nov 2020
14 Jan 2021
19.00p
Q2
13 Aug 2020
08 Oct 2020
19.00p
Q1
14 May 2020
09 Jul 2020
19.00p
Q4
20 Feb 2020
09 Apr 2020
23.00p
Q3
14 Nov 2019
09 Jan 2020
19.00p
Q2
08 Aug 2019
10 Oct 2019
19.00p
Q1
16 May 2019
11 Jul 2019
19.00p
Q4
21 Feb 2019
11 Apr 2019
23.00p
Q3
15 Nov 2018
10 Jan 2019
19.00p
Q2
09 Aug 2018
11 Oct 2018
19.00p
Q1
10 May 2018
12 Jul 2018
19.00p
Q4
22 Feb 2018
12 Apr 2018
23.00p
Q3
09 Nov 2017
11 Jan 2018
19.00p
Q2
10 Aug 2017
12 Oct 2017
19.00p
Q1
11 May 2017
13 Jul 2017
19.00p
Q4
23 Feb 2017
13 Apr 2017
23.00p
Q3
03 Nov 2016
12 Jan 2017
19.00p
Q2
11 Aug 2016
13 Oct 2016
19.00p
Q1
12 May 2016
14 Jul 2016
19.00p
Q4
18 Feb 2016
14 Apr 2016
23.00p
Q4
18 Feb 2016
14 Apr 2016
23.00p
Special
18 Feb 2016
14 Apr 2016
20.00p
Special
18 Feb 2016
14 Apr 2016
20.00p
Special
18 Feb 2016
14 Apr 2016
20.00p
Q3
12 Nov 2015
14 Jan 2016
19.00p
Q2
13 Aug 2015
01 Oct 2015
19.00p
Q1
14 May 2015
09 Jul 2015
19.00p

Dividend Metrics

Year End Date
31 Dec 2024
31 Dec 2023
Dividend growth
5.17%
31.82%
Dividend yield
4.50%
4.00%
Dividend cover
2.61
2.67


Cboe Global Markets® is a registered trade mark of Cboe Global Markets, Inc., a company incorporated in the United States of America with registered address at 400 South LaSalle Street, Chicago, IL 60605, USA. Cboe shall own any and all rights including without limitation Intellectual Property rights and any and all goodwill arising directly or indirectly out of the Recipient’s use of the “Cboe Global Markets®”, “Cboe®” and “Bats®”” trademarks. Neither Cboe nor its licensors accept any liability for any errors or omissions in the Cboe Europe Indices or underlying data. No further distribution of Cboe Europe data is permitted without Cboe’s express written consent.

The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.